Completed PHASE2 INTERVENTIONAL NCT00601016

A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy

Sponsor: Graceway Pharmaceuticals, LLC

Updated 5 times since 2017 Last updated: Jan 24, 2008 Started: Mar 31, 2005 Primary completion: Sep 30, 2006 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00601016, this PHASE2 trial focuses on Hemangioma, Capillary and remains completed. Sponsored by Graceway Pharmaceuticals, LLC, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Graceway Pharmaceuticals, LLC
St. Justine's Hospital

Data source: St. Justine's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada